Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00741455 · OUTCOME

Overall Survival Measured in Participants

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies · Source last updated 2020-11-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 15 Years Post-Transplant

What was measured

Mortality rates in subjects after successful completion of a bone marrow transplant

Groups in this outcome

Study Treatment

Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient. Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later. Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml. G-CSF: 10 mcg/k

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Study Treatment17

Reported measurements

Survival < 1 year post-transplant
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Study Treatment2Not reportedNot reportedNot reportedNot reported
Survival 1 to < 5 years post-transplant
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Study Treatment8Not reportedNot reportedNot reportedNot reported
Survival 5 to < 10 years post-transplant
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Study Treatment0Not reportedNot reportedNot reportedNot reported
Survival 10+ years post-transplant
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Study Treatment7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Survival < 1 year post-transplant
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        8
    title
    Survival 1 to < 5 years post-transplant
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Survival 5 to < 10 years post-transplant
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Survival 10+ years post-transplant
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
Mortality rates in subjects after successful completion of a bone marrow transplant
groups
  1. description
    Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate Stem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient. Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later. Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml. G-CSF: 10 mcg/k
    id
    OG000
    title
    Study Treatment
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 15 Years Post-Transplant
title
Overall Survival Measured in Participants
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice